[Long-term clinical outcome of patients with diabetes and chronic total occlusion underwent drug-eluting stents implantation].
OBJECTIVE
The aim of this study was to assess the long-term clinical outcome of patients with diabetes mellitus and chronic total occlusion (CTO) underwent drug-eluting stents (DES) implantation.


METHODS
Data of 143 consecutive eligible patients from January, 2006 to May, 2007 were retrospectively analyzed. The endpoint of the study was the major adverse cardiac events (MACE), including death, myocardial infarction, target lesion revascularization. The patients were divided into two groups, event group and non-event group, according to the result of follow-up.


RESULTS
Long-term follow-up was finished in 139 (97.2%) patients. Mean follow-up duration was (19.8 + or - 5.1) months. MACE rate was 10.5% during follow-up: 3 deaths, 1 myocardial infarction and 11 repeated target lesion revascularization with PCI. Compared with the non-event group, the percentage of residual lesion [(17.7 + or - 1.8)% vs. (15.4 + or - 5.0)%, P = 0.001] was significantly higher in the event group, however, the final minimal luminal diameter [(2.14 + or - 0.22)% vs. (2.89 + or - 0.37)%, P = 0.004] was lower. Cox regression analysis showed that final luminal diameter (OR: 0.097, 95%CI: 0.013 - 0.694, P = 0.020) was the only dependent predictor at follow-up.


CONCLUSIONS
Final minimal luminal diameter is an independent predictor of MACE during follow-up for patients with diabetes and CTO underwent DES implantation.
Pei
Han-jun
HJ
Coronary Heart Disease Center, Fu Wai Cardiovascular Hospital, Peking Union Medical College and Chinese Academy of Medical Science, Beijing 100037, China.
Wu
Yong-jian
YJ
Yang
Yue-jin
YJ
Chen
Ji-lin
JL
Qiao
Shu-bin
SB
Xu
Bo
B
Li
Jian-jun
JJ
Chen
Jue
J
Song
Guang-yuan
GY
Zhao
Zhen-yan
ZY
Wang
Xi-mei
XM
Gao
Run-lin
RL
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D019917:Blood Vessel Prosthesis Implantation; D002908:Chronic Disease; D054059:Coronary Occlusion / Q000150:complications / Q000175:diagnosis / Q000628:therapy*; D003925:Diabetic Angiopathies / Q000175:diagnosis / Q000628:therapy*; D054855:Drug-Eluting Stents; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D016896:Treatment Outcome